ArticleJournal of Alzheimer's disease reports
Tissue-based assay-confirmed, antibody-negative autoimmune encephalitis responsive to low-dose rituximab in an elderly patient.
Article in Journal of Alzheimer's disease reports. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antibody-negative Autoimmune encephalitis (AE) presents a diagnostic challenge, requiring a high index of clinical suspicion and comprehensive evaluation. We report a 66-year-old man presenting with a seizure accompanied by progressive cognitive decline over several days. Despite the presence of hallmark symptoms and suggestive imaging, the patient was initially misdiagnosed, delaying timely immunotherapy. The diagnosis of antibody-negative AE was made based on clinical criteria, including consistent serological and cerebrospinal fluid (CSF) analyses (negative for known autoimmune and paraneoplastic antibodies), alongside a positive tissue-based assay (TBA), cranial MRI findings, and peripheral blood B-cell profiling. The patient responded well to immunotherapy with a low-dose sequential rituximab regimen, demonstrating clinical improvement and halting disease progression. This case highlights the importance of adhering to diagnostic criteria for AE and integrating TBA into the diagnostic workflow for antibody-negative AE.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.